PPRI Advisory Board

The PPRI Advisory Board was established to provide advice and guidance to the PPRI Secretariat in its vision, management and performance of PPRI-related activities. It aims to promote information exchange between representatives of international and national authorities and agencies working in the pharmaceutical policy field (in particular in the areas of pharmaceutical pricing and reimbursement).
Members of the Advisory Board are experts whose institutions have been members in the PPRI network for at least two years and who represent European and international institutions as well as national competent authorities for pharmaceutical pricing and reimbursement. For national institutions in particular, attention is given to diversity in terms of geographical region, country income level and size, as well as the organisation of the health care and pharmaceutical and medical device system.
The PPRI Advisory Board was established in 2017 and is based on a rotation principle. The first membership term lasted from 2017 until 2020, and the second term from 2021 until 2025. The third term is scheduled from 2026 until 2030. To ensure a good transition, PPRI Advisory Board members of the second term will remain on the Advisory Board until the end of 2026.

As of 2026, members of the PPRI Advisory Board are:

 

For further information see Tasks_Procedures_PPRI_AB_2026_2030_1.pdf.